Teva’s Position on Antimicrobial Resistance (AMR)
Teva Pharmaceutical Industries Ltd (hereinafter “Teva”), including all its directors, executives, employees and subsidiary and affiliated companies, is committed to business practices that address and combat antimicrobial resistance (AMR).

AMR occurs when bacteria and related illnesses become resistant to antibiotics. Without effective antibiotics, infections caused by bacteria, parasites, viruses and fungi can become deadly outbreaks, not just in humans, but also in our global food supply.

As part of our commitment to patients and their health, we recognize our opportunity—and responsibility—to make a meaningful impact on society and the environment. This includes being part of the dialogue and supporting efforts that address some of the most pressing health challenges of our time, such as AMR. We believe in a global collaborative approach and are committed to working with industry peers and global health organizations to identify solutions that protect people and provide new ways to reduce AMR. These beliefs are consistent with our Mission and Values and Code of Conduct.

Our position on AMR is part of our Environmental, Social and Governance (ESG) strategy. It applies to all companies owned or operated by Teva, as well as suppliers and supply chain partners through Teva’s Supplier Code of Conduct.

**Our AMR Aspiration and Commitment**

Since AMR is driven by many interconnected factors and has the ability to impact people across the globe, an international, coordinated approach is critical to accelerate progress.

- We work together with life science industry, health associations and regulators to improve our understanding of AMR and identify solutions. This includes membership in the AMR Industry Alliance, which provides multifaceted, sustainable solutions to reduce AMR, invest in R&D to meet public health needs and improve access to antibiotics, vaccines, and diagnostics.

- We are committed to the responsible production of antimicrobial compounds and minimizing their discharge to the environment from our manufacturing facilities and extended supply chain.

- We support open collaborations between industry and public researchers to overcome the scientific challenges of creating new antibiotics and diagnostics.

- As part of our efforts to increase access to medicines and healthcare, we are committed to supporting mechanisms to ensure affordable access to new and existing antibiotics for people who need them, in all parts of the world and at all levels of income.

- Recognizing the environmental role of AMR, we are committed to efforts that reduce the environmental impact of antibiotics, along with a ‘one health’ approach.
that recognizes the health of people is connected to the health of animals and the environment.

For more information on our latest efforts to understand and address AMR, please visit our latest ESG Progress Report.

**Governance Structure for AMR Management**

Management of AMR is an operational responsibility of each business unit’s line management.

**Application of this Position**

This position is endorsed by Teva’s Board of Directors. We communicate this position to our employees and on our website, and we share our progress in our annual ESG Progress Report.